IVIG To SCIG Transition denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ivig to scig transition are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for the IVIG-to-SCIG Transition

Blue Cross Blue Shield treats the transition from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) as a new prior authorization event — even when the patient has an active authorization for IVIG. This is because BCBS treats route-of-administration changes as a distinct covered service requiring its own clinical review. A prior-authorization denial at this stage is not a finding that SCIG is inappropriate; it is a procedural gate. The right response is to engage the authorization process with complete, well-organized documentation rather than to treat it as a final adverse decision.

## Why This Denial Is Appealable

If the PA request was submitted and denied (rather than simply not yet submitted), the denial is an adverse benefit determination subject to appeal. Under ACA §2719, PA denials can be appealed internally and then externally. Under ERISA §503, employer-plan members have full-and-fair review rights. Your EOB will state the internal appeal deadline (commonly 180 days). External review must typically be requested within 4 months of exhausting internal appeals. If a delay in PA approval puts the patient's health at serious risk, request an expedited prior-authorization review — plans are required to respond on an accelerated timeline for urgent clinical situations.

## The Concrete Appeal Process

1. Confirm whether the PA was denied or whether it simply has not been submitted — these require different responses. 2. If denied: file a formal internal appeal using the denial letter's instructions, attaching the full documentation package below. 3. If not yet submitted: work with the prescriber's office to complete the PA request with all required clinical information before the current IVIG authorization lapses. 4. If internally denied: file for external review within the deadline on the internal denial notice.

## Documentation to Gather

• Diagnosis confirmation: Current chart notes from the treating specialist establishing the condition and its ongoing severity.
• Prior IVIG authorization record: The existing or prior PA approval for IVIG, demonstrating established medical necessity for immunoglobulin replacement.
• IVIG treatment history: Dates of infusions, clinical response, tolerability events, and any access or safety issues that support transitioning to SCIG.
• Prescriber medical-necessity letter: Addresses each criterion in BCBS's published PA criteria for SCIG by name, with specific chart-referenced facts.
• FDA prescribing label: For the ordered SCIG product, confirming FDA approval for the patient's diagnosis.
• Applicable specialty guideline reference: A note that the transition aligns with the relevant professional society's current recommendations.

## Criteria-Mapping Structure

Download the current BCBS prior-authorization criteria for the ordered SCIG product (available on the BCBS provider portal or upon request). Map every criterion to chart evidence:

| PA Criterion | Documented Evidence | |---|---| | [Copy exact criterion from BCBS PA policy] | [Chart note, date, specialist finding] | | [Copy exact criterion from BCBS PA policy] | [Chart note, date, specialist finding] |

Submitting a PA request — or an appeal — that mirrors the plan's own criteria verbatim, with a chart fact for each line, is the single most effective strategy for a quick approval.